Polymer-Cyclodextrin-Lipid Conjugates for Drug Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems face challenges in achieving therapeutic concentrations at target sites with minimal side effects, particularly for poorly water-soluble agents, due to high dosages required for systemic administration, which can lead to allergic reactions and toxicity.
Innovation Solution
The development of polymer-cyclodextrin-lipid conjugates with cyclic oligosaccharides and PEG-lipid complexes that enhance solubility and reduce toxicity by forming inclusion complexes and microemulsions, allowing for improved delivery of hydrophobic compounds through a combination of 'host-guest' mechanisms and micellar solubilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dosages are administered to achieve therapeutic concentrations at target site, then therapeutic effect is improved, but toxicity and allergic reactions increase
Solution Approach 1:
The patent introduces polymer-cyclodextrin-lipid conjugates as intermediary carriers that solubilize hydrophobic drugs, enabling their delivery in aqueous environments at lower concentrations. The cyclodextrin cavity encapsulates hydrophobic drug molecules, while the hydrophilic polymer exterior ensures water solubility, thus achieving therapeutic effects without requiring high dosages that cause toxicity
Solution Approach 2:
The invention creates composite polymer-cyclodextrin-lipid conjugates that combine hydrophilic polymer chains with hydrophobic cyclodextrin cavities and lipid components. This composite structure allows simultaneous interaction with both aqueous environment and hydrophobic drugs, improving drug solubility and delivery efficiency while reducing the dosage required
2Quantity of substance
If polymer-lipid conjugates are used to solubilize hydrophobic drugs, then solubility is improved, but the system requires complex structures like liposomes or microemulsions
Solution Approach 1:
The patent modifies the molecular structure of cyclodextrins by attaching polymer and lipid chains, transforming them from simple cyclic oligosaccharides into amphiphilic conjugates. This parameter change in molecular architecture enables the cyclodextrin derivatives to self-assemble into solubilizing structures without requiring complex liposome or microemulsion formulations
Solution Approach 2:
The invention extracts the essential solubilization function from complex liposome or microemulsion systems and concentrates it into the cyclodextrin cavity-based mechanism. By taking out the core encapsulation capability and embedding it in simpler polymer-cyclodextrin-lipid conjugates, the system achieves drug solubilization without the complexity of vesicular or emulsion structures
Data Source
Figure 1~2(b)
AI summary
The invention comprises compounds, methods of making, and methods of using. A group of polymer-cyclodextrin-lipid conjugates having a center backbone and three or four appended functional groups are disclosed, wherein one of the hydrophilic components is cyclodextrin. The compounds may have a backbone with three or four appended functional groups: one or two lipophilic compounds including sterols or "fat soluble" vitamins or fatty acids, one or two hydrophilic polymer and one cyclodextrin. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the center backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.